1.80

28.57% 0.40

After Hours: 1.68 -0.12 -6.67%

Rezolute Inc (RZLT)

Overview News Price History Financials Discussions Forecast Stock Split

Rezolute Inc stock is traded at $1.80, with a volume of 34.90M. It is up +28.57% in the last 24 hours and down -82.00% over the past month. Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Previous Close:

$1.40

Open:

$1.46

24h Volume:

34.90M

Relative Volume:

8.69

Market Cap:

$166.91M

Revenue:

Net Income/Loss:

$-69.31M

P/E Ratio:

-1.4173

EPS:

-1.27

Net Cash Flow:

$-62.80M

1W Performance:

-82.73%

1M Performance:

-82.00%

6M Performance:

-59.09%

1Y Performance:

-61.21%

1-Day Range:

$1.45

$1.85

1-Week Range:

$1.07

$11.16

52-Week Range:

$1.07

$11.46

Rezolute Inc Stock (RZLT) Company Profile

Name

Rezolute Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

650-206-4507

Address

275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2025-09-17

Latest SEC Filings

RZLT's Discussions on Twitter

Compare RZLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RZLT Rezolute Inc	1.80	129.82M	0	-69.31M	-62.80M	-1.27
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Rezolute Inc Stock (RZLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-24	Initiated	Wedbush	Outperform
Aug-27-24	Initiated	Guggenheim	Buy
Jul-17-24	Initiated	BTIG Research	Buy
Jun-04-24	Initiated	Craig Hallum	Buy
Apr-09-24	Initiated	Maxim Group	Buy
Aug-02-22	Resumed	Canaccord Genuity	Buy
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight
Sep-08-21	Initiated	ROTH Capital	Buy
May-27-21	Initiated	Oppenheimer	Outperform
May-25-21	Initiated	H.C. Wainwright	Buy

View All

Rezolute Inc Stock (RZLT) Latest News

Dec 12, 2025

Jefferies Raises Rezolute’s Price Target Amid Promising Drug Prospects - StocksToTrade

Dec 12, 2025

RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView

Dec 12, 2025

Jefferies Lifts Rezolute’s Target amid New Data Anticipation - timothysykes.com

Dec 12, 2025

Rezolute stock crashes after sole pipeline candidate fails Phase III - Clinical Trials Arena

Dec 12, 2025

Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial - Investing.com Australia

Dec 12, 2025

Rezolute price target lowered to $4 from $20 at Maxim - TipRanks

Dec 12, 2025

Rezolute decimated on Phase III miss for ersodetug - The Pharma Letter

Dec 12, 2025

Rezolute stock price target slashed by Guggenheim after trial failure - Investing.com Nigeria

Dec 12, 2025

RZLT Maintains Buy Rating despite Guggenheim's Lowered Price Tar - GuruFocus

Dec 12, 2025

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts - ts2.tech

Dec 12, 2025